Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Investor Presentation (October 2024)
18 slides from Shuttle Pharmaceuticals's investor presentation, October 2024
Slide 1: Shuttle Pharmaceuticals Holdings, Inc. Investor Presentation Fall 2024
Shuttle Pharmaceuticals Holdings, Inc. Nasdaq: SHPH Investor Presentation Fall 2024
Slide 2: Forward Looking Statements
Forward Looking Statements All of the information contained within this business presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle Pharma” or the “Com
Slide 3: The Fundamental Problem of Radiation Therapy
The Fundamental Problem of Radiation Therapy: Cancers are surrounded by radiation sensitive, dose-limiting normal tissues Sensitization of cancer cells to radiation therapy ▪ Radiation dose determines cancer curability ▪ Radiation therapy limitations are due to sensitive adjacent normal tissues Sens
Slide 4: Company Overview: drugs combined with RT for cancer treatment
Company Overview: drugs combined with RT for cancer treatment Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage pharmaceutical company, developing next generation drugs and diagnostics to improve outcomes for cancer patients treated with radiation therapy (RT). Therapeutics ▪ Ropidoxuridine is a cli
Slide 5: Therapeutics – How does Ropidoxuridine (IPdR) work?
Therapeutics – How does Ropidoxuridine (IPdR) work? Ropidoxuridine (IPdR) is the prodrug of IUdR, a powerful radiation sensitizer, Mechanism reported to improve clinical outcomes of patients treated for brain tumors and After oral administration of Ropidoxuridine (IPdR), sarcomas in NIH supported Ph
Slide 6: Ropidoxuridine (IPdR) – Clinical Asset Development
Ropidoxuridine (IPdR) – Clinical Asset Development ▪ Phase II study of Ropidoxuridine + RT in IDH wild-type, methylation negative glioblastoma patients. ▪ TCG GreenChem manufactured API, University of Iowa Pharmaceuticals formulated the drug product (capsules). ▪ Theradex Oncology provides CRO servi
Slide 7: Therapeutics: Selective HDAC Inhibitor Development
Therapeutics: Selective HDAC Inhibitor Development Therapeutic Pipeline includes histone deacetylase inhibitors for post-RT immune Mechanism stimulation and treatment of ER+ breast cancers. HDAC inhibitors Acetylated Comments and Observations ▪ Novel HDAC inhibitors - discovered and patented by Shut
Slide 8: Therapeutics: HDAC6 selective inhibition with SP-2-225
Therapeutics: HDAC6 selective inhibition with SP-2-225 SP-2-225 inhibits HDAC6, prolongs macrophage polarization in the M-1 (inflammatory state), resulting in an enhanced immunogenic response to cancer antigens and irradiated tumors. Acetylated histones Active transcription The next step is to perfo
Slide 9: Therapeutics: Clinical and Pre-clinical Development Strategies
Therapeutics: Clinical and Pre-clinical Development Strategies 1. Clinical development of Ropidoxuridine & RT • Complete the Phase II clinical trial of Ropidoxuridine & RT in glioblastoma brain tumors • Seek FDA “breakthrough” designation and early marketing approval for glioblastoma indication • Pr
Slide 10: Diagnostics: Clinical Validation of the PC-Rad Test
Diagnostics: Clinical Validation of the PC-Rad Test PC-Rad Test Kit Components • Calibrants for standard vials/ ▪ Market Opportunity: Predictive biomarkers for prostate cancers metabolomics and lipidomics • QC and internal standards ▪ ~ 268,000 new prostate cancer cases annually in the U.S. (inciden
Slide 11: Diagnostics: Product Development – PSMA-B ligand
Diagnostics: Product Development – PSMA-B ligand • The prostate-specific membrane antigen (PSMA) is located on the outside membranes of prostate cancer cells. • The PSMA ligand binds to PSMA, dimerizes, and is internalized into the cell. Radioactive molecules can be attached to the ligand. • Therano
Slide 12: Theranostics: PSMA ligand for diagnosis and treatment
Theranostics: PSMA ligand for diagnosis and treatment Market Opportunity: PSMA imaging and therapy PET Scan Widely metastatic prostate cancer ▪ The Global PSMA PET Imaging Market reached $1.5 billion in 2022 and is expected to reach $2.0 billion by 2030. ▪ PYLARIFY (piflufolastat F-18) is a radioact
Slide 13: Diagnostics: Clinical and Pre-clinical Development Strategies
Diagnostics: Clinical and Pre-clinical Development Strategies 1. Develop the PC-Rad Test intellectual property as a predictive diagnostics test Predictive Biomarker for Prostate Cancer • Establish and validate the predictive assay in the context of use (COU) for FDA approval. • Perform a muti-instit
Slide 14: Shuttle Pharmaceuticals Holdings, Inc. - Intellectual Property
Shuttle Pharmaceuticals Holdings, Inc. - Intellectual Property 1. Ropidoxuridine (radiation sensitizers) ▪ Orphan disease designation, manufacturing technology, and method of use patent for the next generation IPdR/TPI formulation. 2. Selective HDAC inhibitors (radiation sensitizers/immune modulator
Slide 15: Financial Overview
Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of September 30, 2024 Common Stock 2,946,099 Exchange/Ticker NASDAQ: SHPH RSUs Outstanding 53,838 Closing Stock Price* $1.34 Warrants Outstanding 184,000 52 Wk High/Low* $1.03 - $4.94 Total Shares on a Fully Diluted Basis
Slide 16: Experienced Leadership Team
Experienced Leadership Team ▪ Founder & CEO of Shuttle ▪ President & COO of Shuttle ▪ VP Regulatory Shuttle Pharma; Chairman, Board of Pharma 2012 Pharma 2012 Directors since 2017 ▪ CFO Shuttle Pharma ▪ CFO Shuttle Pharma ▪ Former Member, Board of ▪ (2012-2019) 2019 - 2024 Directors, Neopharm Inc. ▪
Slide 17: Board of Directors
Board of Directors Steve Richards, MBA, CPA Milton Brown, MD, PhD Bette Jacobs, PhD Chris Senanayake, PhD Joshua Schafer, MBA Chief Commercial Officer Businessman Vice Dean for Research Professor/Distinguished Scholar CEO, TCG GreenChem & EVP of Business Development CEO, Endurance Media East Virgini
Slide 18: THANK YOU
THANK YOU Shuttle Pharmaceuticals Holdings, Inc. Anatoly Dritschilo, MD, CEO Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org Investor Relations Lytham Partners Robert Blum Tel: (602) 889-9700 Email: SHPH@LythamPartners.com
Shuttle Pharmaceuticals Holdings — Investor Presentation (October 2024) on 6ix